India’s drug pricing authority has capped trade margins on a basket of anti-cancer medicines at 30 percent of the maximum retail price, with revised rates taking effect on November 9, 2026. The order from the National Pharmaceutical Pricing Authority (NPPA) revises ceiling prices across hundreds of brand packs and is expected to cut some maximum retail prices by more than 90 percent. For buyers of Indian generic and biosimilar oncology products, the move resets price benchmarks across the entire anti-cancer supply chain — from manufacturer invoice to hospital billing desk.
⚖️ What the NPPA Order Actually Does
The NPPA capped trade margins at 30 percent of the maximum retail price, excluding GST, on 137 anti-cancer medicines. That 30 percent margin corresponds to a mark-up of 42.86 percent on the price to stockist or distributor (PTS/PTD), according to the NPPA meeting minutes of October 16 and 17, 2026, as reported by The Indian Express. The cap applies irrespective of strength, dosage form, or route of administration, including formulations that combine the listed drugs.
The listed molecules include Atezolizumab, Bevacizumab, Daratumumab, Enzalutamide, Erlotinib, Ipilimumab, Lapatinib, and Pembrolizumab, among others. The list was recommended by an expert committee under the Directorate General of Health Services, constituted to identify drugs essential for cancer treatment. The gazette notification states the revised prices “shall come into effect from 09.11.2026 and shall remain in force until further orders.”
The published price formula is: MRP = Price to Stockist/Distributor x {1 + (Trade Margin / (100 – Trade Margin))} + Applicable GST. In practical terms, if a manufacturer sells a drug to a stockist at Rs 70, the maximum retail price excluding GST works out to Rs 100. The March 2026 PTS/PTD is used as the reference price; where a formulation had no sales that month, the April 2025 to March 2026 sales window is used instead.
📊 Why the Cap Was Needed: Mark-ups up to 700 Percent
Market data analysed at the NPPA meeting found that non-scheduled anti-cancer drugs carried an average trade mark-up of approximately 170 percent, with mark-ups reaching up to 700 percent in certain cases. The Indian Express reported those findings from the authority’s own minutes.
The scale of the distortion is visible in the turnover split. Annual turnover of cancer drugs in India is around Rs 12,500 crore, but scheduled cancer drugs — the segment with directly regulated prices — account for only about Rs 2,250 crore. The remaining majority of the market sat outside direct price control, leaving room for intermediaries to inflate the final bill. The NPPA estimated the cap would reduce maximum retail prices broadly in the 20 to 70 percent range, delivering annual savings of approximately Rs 2,500 crore.
This is not India’s first attempt at the mechanism. A 2019 pilot applied a similar formula to 42 cancer medicines and produced maximum retail price reductions of up to 91 percent, with annual savings of roughly Rs 984 crore. The difference this time is scope: the cap now covers patented products as well as off-patent ones.
💰 How Far Prices Actually Fell: The Count Depends on the Source
Coverage of the notification produced materially different headline figures, and buyers should read the numbers with care. Reports published between October 28 and 31, 2026 cited revised prices for anywhere between 484 and 643 drug brands, with reduction ranges from 69 percent to 93 percent. The variance reflects different ways of counting the same order — by molecule, by brand, or by individual pack strength.
The consistent core, across NDTV Profit, Moneycontrol, Hindustan Times, Firstpost, The New Indian Express, and The South First, is this: the 30 percent trade margin cap applies to 137 listed anti-cancer medicines, revised maximum retail prices take effect on November 9, 2026, and the reduction for generic and biosimilar versions reaches up to 90 to 93 percent for the most inflated packs. Reports that quoted larger brand counts were counting packs, not molecules.
The reductions also expose how much of the patient’s bill was never the drug itself. India Today reported that the newly disclosed maximum retail prices revealed substantial margins built in at the hospital level, where anti-cancer drugs are frequently administered and billed.
🚨 The Gap: High-Cost Patented Brands Largely Untouched
The most important caveat for anyone reading the headline numbers: expensive innovator medicines are largely unaffected in absolute affordability terms. The Economic Times reported on October 31, 2026 that the price cuts leave costly brands untouched, and noted that mark-ups of up to 700 percent had returned after the 2019 round of cuts — evidence that margin discipline decays without enforcement.
Some reports placed the number of high-cost cancer drugs that remain outside the relief at around 65. That figure could not be independently verified across all sources and is marked [CITATION NEEDED]. What is well established is the structural reason: a percentage cap on trade margin compresses the distribution layer, not the manufacturer’s list price. For a patented therapy priced at an already high base, a 30 percent margin cap delivers a smaller absolute saving than it does for a low-priced generic pack carrying an outsized mark-up.
Access advocates have flagged a further design issue. K M Gopakumar of the Working Group on Access to Medicines and Treatments told The Indian Express that patient assistance programmes — where companies supply free vials that are excluded from the base price calculation — can inflate the computed maximum retail price. A study from Tata Memorial Hospital cited in that report found only 1.6 percent of patients who needed patented targeted therapy actually received it, with cost the dominant barrier.
🏭 Compliance Burden Lands on Manufacturers and Hospitals
The order carries enforcement teeth. Manufacturers must submit revised maximum retail price information to NPPA and the relevant state drug controller within seven days of gazette publication, even when there is no price change, and must publish price lists through the Integrated Pharmaceutical Database Management System. Failure to submit is treated as non-reduction of the maximum retail price and can trigger recovery of overcharged amounts under the Drugs (Prices Control) Order.
Supply continuity is also protected. Manufacturers must maintain present production levels; anyone intending to reduce average monthly output needs prior permission from NPPA, and anyone planning to discontinue production or imports must give at least six months’ notice. Where the existing maximum retail price is already below the newly computed ceiling, the lower price must be maintained.
Hospitals and medical institutions have been folded into the compliance perimeter — an unusual step, and a direct response to the fact that oncology drugs are often supplied and billed through institutions rather than retail chemists. Where manufacturers sell directly to a hospital, that institution is treated as the stockist or distributor for the purposes of the calculation, using the manufacturer’s invoice data. Hospitals have been asked to monitor maximum retail prices and report violations to NPPA, and state drug controllers will oversee compliance across manufacturers, dealers, hospitals, and medical institutions.
🔍 What This Means for Generic Medicine Buyers
For international buyers, importers, and distributors sourcing oncology products from India, the November 9 revision changes reference prices, contract terms, and margin expectations at once. A short action list follows.
- Re-baseline your price files before November 9, 2026: any quotation built on pre-revision maximum retail prices for the 137 listed molecules should be treated as stale. Request revised price lists from suppliers under the Integrated Pharmaceutical Database Management System reporting requirement.
- Distinguish molecule count from pack count: when a supplier claims “90 percent cheaper”, confirm whether the saving applies to the specific molecule, brand, and pack strength you are buying. The 137-molecule list is the authoritative scope; brand counts in press coverage vary.
- Verify which products are actually covered: the cap is on trade margin, not on all cancer drugs. Products outside the list, particularly patented therapies, see no guaranteed reduction.
- Confirm your distributor is compliant and licensed: with margins now compressed at the distribution layer, unlicensed or grey-market intermediaries have less room to operate and more incentive to cut corners. For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA member directory.
- Revisit hospital-supply contracts: institutions are now treated as stockists for pricing purposes. If your business model involves institutional supply, the invoice basis for pricing has changed.
- Watch for the next round: the 2019 cuts were followed by mark-ups returning to 700 percent. Verify prices against the current NPPA ceiling rather than assuming a one-time correction holds.
Buyers should also note that compliance obligations run to the state drug controller, not only to NPPA. In practice this means dual verification: check the gazette ceiling and check the state-level enforcement record for the manufacturing site.
📋 Sources
- The Indian Express — “Government caps trade margins on 137 anti-cancer drugs at 30%” (Anonna Dutt, October 18, 2026)
- The Economic Times — “NPPA caps trade margins on 137 cancer drugs at 30%, revised prices from Nov 9” (Teena Thacker, ET Bureau, October 18, 2026)
- The Economic Times — “Cancer drug price cuts leave costly brands untouched” (October 30, 2026)
- NDTV Profit — “Cancer Drug Price Cut: Govt Caps Trade Margins At 30%, Revises Prices Of 543 Drug Brands” (October 28, 2026)
- Hindustan Times — “Cancer drug prices slashed for 543 brands, new rates effective from November 9” (October 28, 2026)
- The South First — “Prices of 484 cancer medicines cut by up to 90% after NPPA caps trade margins” (October 29, 2026)
- India Today — “Cancer drugs up to 93% cheaper: New MRPs expose huge margins by hospitals” (October 28, 2026)
- Firstpost — “Cancer drug prices slashed by up to 69% from November 9 after NPPA directive” (October 28, 2026)
- Moneycontrol — “Anti-cancer drug prices slashed for 543 brands; new MRPs effective from Nov 9” (October 28, 2026)
- The New Indian Express — “Now, pay over 90 per cent less for some cancer meds” (October 29, 2026)
For more information, contact IMSDA at contact@indiamedicine.org.